Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RSV F protein vaccine - Novavax

Next Previous
X
Search
Drug Profile

RSV F protein vaccine - Novavax

Alternative Names: Respiratory syncytial virus fusion protein virus-like particle vaccine - Novavax; Respiratory syncytial virus vaccine - Novavax; ResVax; RSV F protein recombinant nanoparticle vaccine; RSV F Vaccine; RSV F-protein nanoparticle vaccine; RSV-F; RSV-F nanoparticle protein micelle vaccine; RSV-F VLP vaccine - Novavax

Latest Information Update: 28 May 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novavax
  • Class Protein vaccines; Proteins; Respiratory syncytial virus vaccines; Synthetic vaccines; Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Respiratory syncytial virus infections

Most Recent Events

  • 28 May 2021 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In children, Prevention) in Canada (IM, Injection)
  • 12 May 2020 RSV F protein vaccine - Novavax is available for licensing in World as of 12 May 2020. https://novavax.com/
  • 02 Oct 2019 Efficacy, adverse events and immunogenicity data from the phase III Prepare trial in Respiratory syncytial virus infections presented at the IDWeek 2019 (IDW-2019)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top